Loading
A phase 2 trial of SAL-0951 tablets 4mg in advanced solid tumours, run by Shenzhen Salubris Pharmaceuticals Co., Ltd., now recruiting.
SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies is a phase 2 interventional study registered as NCT06737081 by Shenzhen Salubris Pharmaceuticals Co., Ltd., with 60 participants planned, started 2024-09-14 and due to reach its primary completion in 2025-12-31. Interventions recorded: SAL-0951 tablets 4mg and SAL-0951 tablets 5mg.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/